Piramal Pharma Share Price Today | Stock Price & Piramal Pharma Share Screener
As of November 18, 2026, the live Piramal Pharma share price (NSE: PPLPHARMA) is ₹238.95 on NSE and ₹238.95 on BSE, down 0.73% from the previous close, with shares trading between ₹237.32 and ₹243.76 in today's trading session, and a 52-week range of ₹133.27–₹246.37. Track PPLPHARMA company valuation to gauge the company's total market size. Use the Piramal Pharma stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Piramal Pharma opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Key Statistics and Valuation Ratios
Over the trailing twelve months the company reported revenue of ₹2,671 and net income of ₹5, with EBITDA of ₹402, an operating margin of 13.0% and a profit margin of 0.2%.
Piramal Pharma Share Price Chart
Track the current stock price of Piramal Pharma with an interactive chart. Analyse PPLPHARMA share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Piramal Pharma stock quote in one place.
The quote of ₹238.95 sits between the 52-week low of ₹133.27 and the 52-week high of ₹246.37, and the latest session moved -0.73% from the previous close.
Piramal Pharma Company Profile - Fundamental Screener
Screen Piramal Pharma company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for PPLPHARMA shares across the equity market and its stock price history, plus the wider market trend.
The company is classified under the Healthcare sector and the Pharmaceuticals & Biotechnology industry, with Nandini Piramal listed as chairperson or CEO, and it trades under ISIN INE0DK501011.
Business Overview
Piramal Pharma Limited is an Indian pharmaceutical company incorporated in 2020. It offers a diverse portfolio of products and services through 17 global facilities and distribution in over 100 countries. The company operates through three main segments: an integrated Contract Development and Manufacturing Organization (CDMO) business, a Complex Hospital Generics...more
Company Details
Classification
Identifiers and Leadership
Piramal Pharma Balance Sheet Screener
Screen PPLPHARMA balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.
For 2026, total assets were ₹17,965, up from ₹15,678 in 2025.
Latest statistics put total assets at ₹17,965 and shareholder funds at ₹8,163, with a leverage ratio of 0.65.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
Assets |
||||||
| Total Assets | 17,965 | 15,678 | 15,312 | 14,523 | 12,797 | 10,900 |
| Current Assets | 0 | 0 | 0 | 0 | 0 | 0 |
| Fixed Assets | 8,684 | 8,133 | 7,990 | 7,469 | 6,879 | 6,106 |
Liabilities |
||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 5,044 | 3,786 | 3,031 | 3,906 | 3,067 | 2,805 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
Shareholders' Equity |
||||||
| Total Equity | 8,163 | 8,126 | 7,911 | 6,774 | 6,697 | 5,605 |
| Share Capital | 1,327 | 1,324 | 1,323 | 1,193 | 1,186 | 995 |
| Reserves & Surplus | 6,836 | 6,801 | 6,588 | 5,580 | 5,511 | 4,610 |
Piramal Pharma Income Statement Screener - Profit & Revenue Analysis
Screen Piramal Pharma income statement and profit fundamentals. Analyze PPLPHARMA quarterly results. Piramal Pharma reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.
For 2026-Sept, revenue was ₹2,671 and net profit was ₹5, equal to earnings per unit of ₹0.04, at an operating margin of 13%.
In that period expenses were ₹2,268, interest cost ₹88 and tax ₹77. The next period listed, 2026-Jun, shows revenue of ₹2,379 and net profit of ₹-69.
| Item | 2026-Sept | 2026-Jun | 2026-Mar | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec | 2023-Sept | 2023-Jun | 2023-Mar |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue and Expenses | |||||||||||||||
| Revenue | 2,671 | 2,379 | 2,811 | 2,193 | 2,124 | 2,031 | 2,812 | 2,233 | 2,320 | 1,993 | 2,591 | 2,034 | 1,980 | 1,802 | 2,196 |
| Expenses | 2,268 | 2,075 | 2,467 | 1,985 | 1,885 | 1,827 | 2,193 | 1,867 | 1,900 | 1,747 | 2,053 | 1,723 | 1,646 | 1,617 | 1,812 |
Operating Costs and Margins | |||||||||||||||
| EBITDA | 402 | 304 | 344 | 208 | 239 | 204 | 619 | 367 | 420 | 246 | 538 | 312 | 334 | 185 | 384 |
| Operating Profit % | 13.00% | 9.00% | 10.00% | 7.00% | 8.00% | 6.00% | 20.00% | 15.00% | 15.00% | 10.00% | 20.00% | 12.00% | 14.00% | 8.00% | 16.00% |
| Depreciation | 233 | 224 | 218 | 213 | 203 | 197 | 243 | 197 | 192 | 185 | 196 | 186 | 185 | 174 | 184 |
| Interest | 88 | 88 | 83 | 89 | 82 | 86 | 104 | 103 | 108 | 107 | 114 | 106 | 110 | 119 | 104 |
Profit and Earnings | |||||||||||||||
| Profit Before Tax | 82 | -8 | 43 | -94 | -46 | -79 | 273 | 67 | 120 | -45 | 228 | 19 | 40 | -107 | 95 |
| Tax | 77 | 62 | 52 | 42 | 53 | 3 | 119 | 63 | 98 | 44 | 126 | 9 | 35 | -9 | 45 |
| Net Profit | 5 | -69 | -9 | -136 | -99 | -82 | 154 | 4 | 23 | -89 | 101 | 10 | 5 | -99 | 50 |
| EPS | 0.04 | -0.52 | -0.07 | -1.03 | -0.75 | -0.62 | 1.16 | 0.03 | 0.17 | -0.67 | 0.77 | 0.08 | 0.04 | -0.83 | 0.42 |
Piramal Pharma Cash Flow Screener - Liquidity Fundamentals
Screen PPLPHARMA cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.
In 2026-March, operating activities generated ₹1,653, and net cash flow was an inflow of ₹794.
Over the same period, investing activities used ₹820 and financing activities used ₹39.
| Item | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March |
|---|---|---|---|---|---|---|
Cash from Operations and Investing | ||||||
| Operating Activities | 1,653 | 892 | 1,005 | 484 | 766 | 598 |
| Investing Activities | -820 | -488 | -416 | -1,334 | -1,737 | -4,464 |
Financing and Net Cash | ||||||
| Financing Activities | -39 | -441 | -422 | 818 | 794 | 3,977 |
| Net Cash Flow | 794 | -37 | 166 | -32 | -177 | 110 |
Piramal Pharma Shareholding Pattern Screener
See Piramal Pharma shareholding pattern with promoter, FII, and DII holdings. Check Piramal Pharma promoter holding and ownership changes for PPLPHARMA on TickJournal, and see how institutional stock price moves affect the market.
In 2026-Mar, promoters held 34.86%, foreign institutions 30.18%, domestic institutions 15.61% and the public 13.74%, spread across 450,661 shareholders.
The shareholder count was 450,661 in 2026-Mar, compared with 461,096 in 2026-Jun.
| Item | 2026-Mar | 2026-Jun | 2026-Sept | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar |
|---|---|---|---|---|---|---|---|---|
Promoter Holding | ||||||||
| Promoter Holding | 34.86% | 34.80% | 34.80% | 34.95% | 34.86% | 34.86% | 34.86% | 35.02% |
Institutional Investors | ||||||||
| FII Holding | 30.18% | 12.52% | 13.65% | 31.49% | 30.86% | 30.27% | 29.66% | 30.59% |
| DII Holding | 15.61% | 14.57% | 14.44% | 14.78% | 14.26% | 14.89% | 15.69% | 12.12% |
Government, Public and Others | ||||||||
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 13.74% | 14.54% | 13.27% | 13.11% | 14.07% | 14.12% | 14.11% | 15.13% |
| Other Holding | 5.61% | 23.57% | 23.84% | 5.66% | 5.95% | 5.86% | 5.69% | 7.14% |
| Shareholder Count | 450,661 | 461,096 | 413,197 | 432,843 | 458,430 | 462,511 | 453,830 | 297,996 |
Dividend Yield Screener - Share Price & Share Analysis
Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Piramal Pharma. Piramal Pharma dividend yield can be compared with peers and other stocks in the market.
The latest dividend recorded was ₹0.00 per unit for 2026-March, a yield of 0.00%, compared with ₹0.00 for 2025-March.
Dividends are listed for 10 periods, with the three most recent payouts at ₹0.00, ₹0.00 and ₹0.11 per unit.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹0.00 | 0.00% |
| 2024-March | ₹0.11 | 0.05% |
| 2023-March | ₹0.00 | 0.00% |
| 2022-March | ₹0.56 | 0.84% |
| 2021-March | ₹0.00 | 0.00% |
| 2020-March | ₹0.00 | 0.00% |
| 2019-March | ₹0.00 | 0.00% |
| 2018-March | ₹0.00 | 0.00% |
| 2017-March | ₹0.00 | 0.00% |
Piramal Pharma Stock Index Membership - Nifty & Sensex
See which indices include Piramal Pharma stock. Check PPLPHARMA index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.
The company is listed in 21 indices, including BSE 1000.
Among the benchmarks tracked are BSE 1000, BSE INDEX BSE HC, BSE INDEX BSE500, BSE INDEX BSEIPO.
Complete Index List
Piramal Pharma Market Events Screener - Corporate Actions
Get Piramal Pharma corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Piramal Pharma stock events that may affect PPLPHARMA share price, along with derivatives, futures and options activity and sector gainers.
15 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated October 27, 2026, with a record date of October 27, 2026.
It is followed by Annual General Meeting dated July 30, 2026 and Quarterly Result Announcement dated July 29, 2026.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-10-27 | 2026-10-27 | Quarterly Result Announcement | NA | 0.38% |
| 2026-07-30 | 2026-07-30 | Annual General Meeting | NA | 16.34% |
| 2026-07-29 | 2026-07-29 | Quarterly Result Announcement | NA | 7.79% |
| 2026-04-28 | 2026-04-28 | Quarterly Result Announcement | NA | 14.47% |
| 2026-01-28 | 2026-01-28 | Quarterly Result Announcement | NA | -9.31% |
| 2025-11-05 | 2025-11-05 | Quarterly Result Announcement | NA | -1.56% |
| 2025-07-30 | 2025-07-30 | Annual General Meeting | NA | 2.83% |
| 2025-07-28 | 2025-07-28 | Quarterly Result Announcement | NA | -6.75% |
| 2025-07-16 | 2025-07-16 | Dividend | ₹ 0.14 /share | 0.61% |
| 2025-05-14 | 2025-05-14 | Quarterly Result Announcement | NA | -0.02% |
| 2025-01-28 | 2025-01-28 | Quarterly Result Announcement | NA | 1.24% |
| 2024-10-23 | 2024-10-23 | Quarterly Result Announcement | NA | -2.78% |
| 2024-07-26 | 2024-07-26 | Annual General Meeting | NA | 5.86% |
| 2024-07-12 | 2024-07-12 | Dividend | ₹ 0.11 /share | 2.40% |
| 2023-08-02 | 2023-08-02 | Rights | 5:46 | 1.87% |
Piramal Pharma Competitors Screener - Peer Stocks Comparison
Screen PPLPHARMA competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.
The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 448,676 | 40.80 | 61,674 | 12.69% | 11,565 | 60.46 |
| Divis Laboratories | 295,997 | 87.70 | 11,067 | 13.95% | 2,568 | 68.76 |
| Torrent Pharmaceuticals | 177,586 | 85.00 | 13,886 | 20.34% | 2,138 | 47.23 |
| Laurus Labs | 126,325 | 89.90 | 6,868 | 22.01% | 890 | 57.04 |
| Zydus Life Science | 120,119 | 27.60 | 27,658 | 17.64% | 5,026 | 55.91 |
| Dr Reddys Laboratories | 115,854 | 41.80 | 35,059 | 3.90% | 4,158 | 71.26 |
| Cipla | 112,131 | 39.50 | 29,045 | 2.24% | 3,870 | 53.06 |
| Mankind Pharma | 107,805 | 47.90 | 14,636 | 14.85% | 1,938 | 61.37 |
| Aurobindo Pharma | 103,229 | 25.80 | 34,145 | 5.56% | 3,503 | 60.39 |
| Lupin | 89,172 | 17.30 | 29,039 | 26.75% | 5,356 | 39.39 |
Piramal Pharma Company Announcements - News & Reports Screener
Screen PPLPHARMA latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.
20 recent announcements are listed, the latest dated October 31, 2026.
The next most recent announcements are dated October 30, 2026 and October 30, 2026.
| Date | Update | Actions |
|---|---|---|
| 2026-10-31 | Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 | - |
| 2026-10-30 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-10-30 | Announcement under Regulation 30 (LODR)-Earnings Call Transcript | - |
| 2026-10-28 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | - |
| 2026-10-27 | Announcement under Regulation 30 (LODR)-Investor Presentation | - |
| 2026-10-27 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-10-27 | Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Quarter Ended September 30 2026 | - |
| 2026-10-27 | Board Meeting Outcome for Outcome Of Board Meeting Of Piramal Pharma Limited Held On 27Th October 2026 | - |
| 2026-10-16 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-10-16 | Board Meeting Intimation for Considering And Approving The Unaudited Financial Results (Standalone And Consolidated) Of The Company For Quarter And Half Year Ended 30Th September 2026 | - |
| 2026-10-01 | Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Expiry And Non-Renewal Of Commercial Arrangement With Bayer Pharmaceuticals Private Limited | - |
| 2026-10-01 | Clarification On News Item Which Appeared In The Www.Thehindubusinessline.Com Dated September 30 2026 Captioned Ontario Contributes $1.7 Million Investment To Advance Life Sciences Innovation At Piramal PharmaS Aurora Facility. | - |
| 2026-09-30 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-09-30 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-09-30 | Clarification sought from Piramal Pharma Ltd | - |
| 2026-09-29 | Closure of Trading Window | - |
| 2026-09-29 | Disclosure Under Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 | - |
| 2026-09-18 | Disclosure Under Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 - ESG Rating -Niche Ninety Nine Capability And Certifications (OPC) Private Limited | - |
| 2026-09-14 | Disclosure Under Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 - FDA Inspection | - |
| 2026-09-08 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
Frequently Asked Questions
How is the company valued right now?
The current quote is ₹238.95, within a 52-week range of ₹133.27 to ₹246.37. The P/E ratio is -156.10 and the P/B ratio is 4.00, with earnings per unit of ₹0.04. Market capitalisation stands at ₹32,045.55 Cr and the dividend yield is 0.06%. The company operates in the Healthcare sector, in the Pharmaceuticals & Biotechnology industry, so compare these ratios with its sector peers in the table above.
About This Data
Quotes are sourced from the NSE and the BSE. Key statistics were last updated on November 19, 2026. This page covers 6 balance sheet periods, 15 income statement periods, 6 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.